Koers Regen BioPharma, Inc. Other OTC
Aandelen
RGBP
US75886M1027
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 236K 220K | Omzet 2023 | 237K 221K | Marktkapitalisatie | 6,33 mln. 5,92 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 2 mln. 1,87 mln. | Nettowinst (verlies) 2023 | 1 mln. 935K | EV/omzet 2022 | 144 x |
Nettoschuld 2022 | 1,22 mln. 1,14 mln. | Nettoschuld 2023 | 635K 594K | EV/omzet 2023 | 29,4 x |
K/w-verhouding 2022 |
13,7
x | K/w-verhouding 2023 |
6,24
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 91,14% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Koos
CEO | Chief Executive Officer | 64 | 24-04-12 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Koos
CEO | Chief Executive Officer | 64 | 24-04-12 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |